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Abstract
Purpose
To characterize accumulation of drug-modifiable cardiovascular (CV) risk factors in statin
initiators who had no prior medication or hospitalizations for CV disease or diabetes.
Methods
A cohort of 45-75-year-old statin initiators in Finland with no prior CV diseases, diabetes or
medication for these conditions was followed up for 24 months after statin initiation for accu-
mulation of CV and diabetes drugs. The number of drugs was measured semi-annually
since the first statin purchase and analyzed by growth mixture modeling.
Results
Of the 11 948 apparently healthy statin initiators, 34% purchased at least one additional CV
or diabetes drug during the subsequent 24 months. Of those, 20% redeemed no other CV
or diabetes drugs at statin initiation but started to accumulate them after 18 months of fol-
low-up, receiving on average 1.3 other drugs at 24 months. The majority, 59%, redeemed
on average 0.5 drugs at statin initiation and accumulated 1.5 drugs by the end of 24-month
follow-up. Seventeen percent received 1 additional drug at statin initiation, accumulating on
average 3 drugs. The remaining 4% with an average of 2 CV or diabetes drugs at statin initi-
ation redeemed 3.5 additional drugs during the follow-up.
Conclusions
Two years after statin initiation, 2 in 3 apparently healthy initiators could still be defined as
such as reflected by CV and diabetes medication use.
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Introduction
During the last 15 years, recommendations and indications for statin therapy have broadened
from secondary prevention (prevention of progression of the disease and prevention of recur-
rent events in patients with existing cardiovascular [CV] disease) [1–3] to primary prevention
of CV disease in individuals with CV risk factors [4,5]. Implementation of the current recom-
mendations is likely to place a significant burden on societies and insurers. For example, fol-
lowing the criteria of the 2013 guideline [5] from the American College of Cardiology (ACC)
and the American Heart Association (AHA) could result in about 1 in 3 American adults (of
whom ~33 million at7.5% and ~12 million at 5.0–7.4% 10-year risk of an atherosclerotic CV
event) being recommended for consideration of statin therapy [6]. Even in the era of generic
statins, however, statin therapy in low-risk populations may not be universally cost-effective
[7–9].
In population-based studies that have classified statin initiators by their estimated CV dis-
ease risk level, a shift towards low-risk individuals has been found, including those with no CV
disease, diabetes, or prior medication for these conditions. In British Columbia, Canada, 17%
of statin initiators in 1996–2001 had no marker of previous CV disease in the hospital dis-
charge register or in the prescription register [10]. In Denmark, the proportion of statin initia-
tors with no prior CV disease, diabetes, or medication for these conditions increased from 20%
to 26% between 1996 and 2009 [11]. A similar shift, from 24% to 28%, was observed in Finland
between 1999 and 2008 [12].
In the population-based studies, initiators defined as being at low CV disease risk at the
time of statin initiation may, however, be misclassified as such if the definition is based on reg-
ister data on the period prior to or on the date of the initiation. Various CV risk factors may be
clinically present at the time of statin initiation but not detectable in health care registers until
later as they can be targeted one at a time. In this study, the aim was to characterize accumula-
tion of CV and diabetes medication as indicators of multiple CV risk factors among apparently
healthy statin initiators defined as individuals aged 45–75 years who had no prior medication
or hospitalizations for CV disease or diabetes. We applied growth mixture modeling to gain
understanding about accumulation of CV and diabetes medication during a 2-year follow-up.
To our knowledge, this kind of information has not been published previously.
Materials and Methods
Data sources
We used data from administrative databases generated through the universal health care and
drug reimbursement systems covering the 5.4 million residents of Finland. We identified pre-
scription records with the Prescription Register run since 1994 and managed by the Social In-
surance Institution (SII) [13]. This register contains records of prescription drug purchases
reimbursed to residents in non-institutional settings. For each drug, the data include the dis-
pensing date, the Anatomical Therapeutic Chemical (ATC) classification code [14], and the
quantity dispensed. Patients staying at public nursing homes or hospitals without interruption
for over 90 days are not eligible for drug reimbursement, and their purchases are not registered.
These long-term institutionalized patients can be identified by a separate SII register.
We identified hospitalizations from the Finnish Care Register, managed by the National In-
stitute for Health andWelfare. The register, covering all Finnish hospitals, includes individual
administrative data on main and additional discharge diagnoses, and the admission and dis-
charge dates. The 10th revision of the International Classification of Diseases (ICD-10) has
Accumulation of Cardiovascular and Diabetes Drugs
PLOS ONE | DOI:10.1371/journal.pone.0117182 February 6, 2015 2 / 12
Orion Corporation as an Independent External
Member of a Data Monitoring and Safety Committee
in a clinical trial, and assisted Santen Pharmaceutical
Co. in pharmacokinetic calculations. PL has no
conflict of interest. The authors declare no other
financial or non-financial (professional or personal)
conflict of interests. The authors declare that their
competing interests do not alter their adherence to
PLOS ONE policies on sharing data and materials.
been in use since Jan 1, 1996. The data from the above databases were linked anonymously
using encrypted personal identifiers.
Design
A cohort of initiators of simvastatin (ATC code C10AA01), lovastatin (C10AA02), pravastatin
(C10AA03), fluvastatin (C10AA04), atorvastatin (C10AA05), or rosuvastatin (C10AA07) ther-
apy between Apr 1 and Dec 31, 2006 and aged 45–75 years was followed up for 730 days (24
months) for accumulation of CV or diabetes medication. The initiation was defined as not hav-
ing purchased any statin (C10AA01–C10AA07, C10BA02) since Jan 1, 1994. In addition, we
excluded those who had purchased CV medication (antithrombotic agents [ATC class B01],
cardiac glycosides [C01A], antiarrhythmic drugs [C01B], nitrates [C01DA], centrally acting
antihypertensive drugs [C02], diuretics [C03], peripheral vasodilators [C04], beta blockers
[C07], calcium channel blockers [C08], angiotensin-converting enzyme [ACE] inhibitors
[C09A, C09B], or angiotensin receptor blockers [ARB] [C09C, C09D]) or diabetes drugs (A10)
during 3 years preceding statin initiation. Furthermore, those hospitalized for diabetes (ICD-
10 codes E10–E14), hypertension (I10–I14), atherosclerotic CV disease (I20–I25, I63, I69.3,
I70, I71), cardiac insufficiency (I50), or for coronary revascularization procedures in the pre-
ceding 7 years and those hospitalized for atrial fibrillation (I48) during the preceding year were
excluded. In addition, individuals living in institutions within 3 years prior to the initiation
were excluded. The outcome of interest was semi-annually measured accumulated number of
CV and diabetes drugs as listed above, a surrogate of CV risk factors. The follow-up started on
the date of the first statin purchase and ended in death, long-term institutionalization, or after
730 days (24 months) of follow-up, whichever came first. The vital statistics came from the SII.
We described the latent classes (see below) according to age at statin initiation, sex, and hospi-
talizations for other than CV disease or diabetes diagnoses in the 365 days preceding the
initiation.
Adherence to statin therapy during the first year of statin use was measured as the propor-
tion of days covered (PDC); i.e. the number of tablets available to the patient divided by 365
[15]. The use of statin therapy during the second year of follow-up was defined as having a stat-
in purchase during the second year or as having tablets left over from a previous purchase
taken place during the first 365 days.
Statistical analyses
We applied growth mixture modeling to identify unobserved homogeneous subpopulations
(latent classes) within a larger heterogeneous population and to group patients according to
the similarities of their trajectories on accumulating CV and diabetes drugs over the 24-month
follow-up using the Mplus Version 7 program [16]. Growth mixture modeling is based on an
assumption that each individual’s count over time results from him/her being a member of a
latent, unobserved class while conventional growth models assume that individuals come from
a single population and estimate a single growth factor that might lead to an oversimplified es-
timate of change among individuals with different health status [17–18]. In addition to identi-
fying subpopulations in a post-hocmanner, growth mixture models (GMM) describe
differences in change between and within the unobserved subpopulations.
The outcome variable, defined as the cumulative number of distinct CV or diabetes drugs
(identified by the fifth ATC level, excluding statins), was measured semi-annually since the
date of the first statin purchase and it was assumed to be Poisson distributed. When construct-
ing the models, we started by considering linear and quadratic trends over time for the ob-
served outcome variables with 1 to 5 latent classes. We evaluated the appropriateness of the
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models using Bayesian information criteria (BIC), with the smallest value indicating the best
fit, and the Lo-Mendell-Rubin Likelihood Ratio test, with P-values less than 0.05 indicating
that a more parsimonious model fits data worse than a model with more parameters [19]. In
GMMs, each individual’s probabilities to belong to each of the latent classes are calculated
based on how her/his trajectories match the mean trajectory of each of the classes. Probabilities
are then used to assign individuals to the class they most likely belong to. Classification accura-
cy was evaluated using the entropy value ranging between 0 and 1, with larger values indicating
better accuracy. No less than 1% of the total count in a class was accepted when determining
the number of classes.
To aid convergence, variances of linear and quadratic growth factors were fixed to zero [17].
All the models were fitted using random starts, and the estimates from the final model pre-
sented here were replicated by rerunning the model with the seeds that produced the best 2
log-likelihood values. This was done to check that results did not arise from local maxima.
Once the best fitting model had been identified, we compared baseline characteristics of the la-
tent classes by one-way analysis of variance and the Chi-Square test. Analyses are valid under
missing at random assumption, i.e. missing values were not imputed but, instead, parameters
and standard errors were estimated with all available data.
Ethics Statement
Data were obtained from the databases hosted by the Social Insurance Institution and the Na-
tional Institute for Health and Welfare, Helsinki, Finland that are not public repositories. The
Social Insurance Institution and the National Institute for Health andWelfare approved the
study protocol. There was no legal requirement for an ethics committee approval because re-
searchers used only de-identified register data and the individuals in the registers were not con-
tacted. No written consent from patients was required either.
Results
During the last three quarters of 2006, statin therapy was initiated by 37 707 individuals aged
45–75 years (Fig. 1). Of them, 31.7% (11 948) were apparently healthy, i.e., they had no register
marker of prior CV disease, diabetes, or medications indicated for these conditions. During the
subsequent 24 months since statin initiation, 65.7% (7 851) of these apparently healthy individ-
uals had no purchases of CV or diabetes drugs in addition to statins. Of the remaining 4 097
(34.3%) patients who initiated other CV or diabetes drugs during the follow-up, 42.0% (1 719)
initiated another CV or diabetes drug on the day of the statin initiation and altogether 66.1% (2
699) during the first 6 months of the follow-up.
The 4 097 patients who initiated additional drugs were older than those who did not (mean
age: 59.3 years [SD = 7.69] versus 58.0 [7.35] years, p<0.001). Of women, 31.8% (1 985) and of
men, 37.0% (2 112) initiated other CV or diabetes medication (Table 1). The proportion of
those who had been hospitalized in the year preceding statin initiation was higher among the
initiators than non-initiators, 15.9% vs. 11.8% in women and 17.7% vs. 10.7% in men
(Table 1). Of the initiators of other CV or diabetes medication 1.2% (47) and of the non-initia-
tors 0.7% (56) were long-term institutionalized or died during the follow-up.
Typically, other CV or diabetes drugs were initiated one at a time (85.5% of all initiated
drugs during the follow-up) but it was also common to initiate 2 drugs simultaneously (10.7%).
During the 24-month follow-up, 51.4% of the initiators of other drugs purchased ACE inhibi-
tors/ARB inhibitors, 33.4% beta blockers, 17.9% diabetes drugs, and 17.3% nitrates (S1 Table).
Of the drugs purchased on the day of statin initiation, beta-blockers, calcium channel blockers,
diuretics, centrally acting antihypertensive drugs and ACE inhibitors/ARB accounted for
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68.2% (1 482) while nitrates accounted for 12.7% (277) and diabetes drugs for 11.4% (247) (S1
Table). Of the 732 diabetes drug initiations, 52.3% (383) took place during the first 6 months
(including the statin initiation date) and 14.8% (108), 17.8% (130) and 15.2% (111) in the three
6-month periods thereafter (S1 Table).
GMMs were fitted using data from the 4 097 individuals who initiated at least one other CV
or diabetes drug during the 24-month follow-up. Based on the lowest BIC value and estimabil-
ity, we chose the quadratic 4-class GMM as our final model (Table 2). This model is graphically
presented in S1 Fig. Estimated trajectories from the selected 4-class quadratic GMM are pre-
sented in Fig. 2. A majority (59.2%) of the individuals who started other CV or diabetes drugs
during the follow-up were classified to the “low accumulation” group where patients redeemed
typically one other drug during the 6 months after statin initiation. The count remained low
until the end of follow-up, being on average 1.5 drugs at 24 months. One fifth of the individuals
(20.1%) (the group of “low and slow accumulation”) did not redeem any other CV or diabetes
drug simultaneously with the first statin, but started to accumulate them after 18 months, end-
ing up with on average 1.3 CV or diabetes drugs at 24 months. Of the initiators of other drugs,
17.1% were classified to the “moderate accumulation” group that purchased one additional
CV or diabetes drug at statin initiation and on average 3 drugs by the end of follow-up. The
Fig 1. Patient flow between 1st Apr and 31st Dec 2006 with the 24-month follow-up (CV = cardiovascular).
doi:10.1371/journal.pone.0117182.g001
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remaining 3.6% were classified to the “high accumulation” group that redeemed an average of
2 CV or diabetes drugs on the day of statin initiation and a further 3.5 drugs during the follow-
up, ending up with an average of 5.5 drugs.
Of the patients in the “high accumulation” group, 86.0% persisted with statins after the first
year of follow-up (Table 3). Corresponding figures were 81.4% for the “moderate accumula-
tion”, 80.7% for the “low and slow accumulation”, and 78.2% for the “slow accumulation”
groups. Of the patients not initiating additional drugs, 73.5% continued statin therapy after the
first year (not shown in Table 3). Also PDC was the lowest in patients not initiating other
drugs (data not shown).
Patients in the “high accumulation” and “moderate accumulation” groups were more often
male and older and had more commonly been hospitalized during the year preceding statin
initiation than patients in the “low and slow accumulation” or “low accumulation” groups
(Table 3).
Discussion
In Finland in 2006, the majority of apparently healthy statin initiators did not have CV risk fac-
tors modifiable by drug therapy as two thirds of the initiators deemed free of atherosclerotic
CV disease or diabetes at the initiation did not purchase any other drugs used to treat or pre-
vent these conditions during the subsequent 2 years. About one in 7 (~14%) initiators, howev-
er, filled a prescription for at least one other CV or diabetes drug already with their first statin
prescription. Overall, four clinically different patterns of accumulating CV and diabetes drugs
emerged among those statin initiators who purchased additional medication within the subse-
quent 2 years.
The estimated patterns of accumulating CV and diabetes drugs differed from each other in
terms of number and rate of accumulated drugs. Clinically, the low and slow, and the low accu-
mulation groups were similar, and together they accounted for 81% of the apparently healthy
statin initiators (Table 3). In these groups, individuals purchased on average 0–0.5 other CV or
Table 1. Characteristics of the 11 948 apparently healthy* statin initiators stratiﬁed by purchase of other cardiovascular or diabetes drugs
during the 24-month follow-up.
Women Men
n = 6 246 (52.3%) n = 5 702 (47.7%)
Purchases of other
drugs
Without
purchases
Purchases of other
drugs
Without
purchases
n = 1 985 (31.8%) n = 4 261
(68.2%)
n = 2 112 (37.0%) n = 3 590
(63.0%)
Age group, n (%)
45–49 158 (8.0) 357 (8.4) 287 (13.6) 677 (18.9)
50–59 785 (39.5) 1 906 (44.7) 945 (44.7) 1 746 (48.6)
60–69 748 (37.7) 1 594 (37.4) 669 (31.7) 927 (25.8)
70–75 294 (14.8) 404 (9.5) 211 (10.0) 240 (6.7)
Age, mean (SD) 60.4 (7.6) 59.2 (7.1) 58.3 (7.6) 56.6 (7.4)
Died during the follow-up, n (%) 6 (0.3) 14 (0.3) 25 (1.0) 28 (0.8)
Long-term institutionalized during the follow-up, n (%) 8 (0.6) 5 (0.1) 8 (0.4) 9 (0.3)
Hospitalized for other than cardiovascular diseases during 365
days prior to statin initiation, n (%)
316 (15.9) 502 (11.8) 374 (17.7) 384 (10.7)
* no record of prior cardiovascular diseases or diabetes in the hospital discharge register within 7 years or medication for these conditions within 3 years
doi:10.1371/journal.pone.0117182.t001
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diabetes drugs at statin initiation and no more than on average 1.3–1.5 drugs had accumulated
by the end of the follow-up. In both groups one in four patients purchased beta blockers, most
likely prescribed for either hypertension or coronary heart disease. Nitrates were purchased by
12% of the individuals in the low and slow and by 10% of those in the low accumulation group.
Individuals in both of these groups can be assumed to have at least moderately increased
CV risk.
The moderate and high accumulation groups differed clinically more clearly from each
other (Fig. 2, Table 3). Of the individuals in the moderate accumulation group 61% and 92% of
those in the high accumulation group purchased beta blockers (Table 3). Individuals in both
groups were obviously at high CV risk already at the time of statin initiation.
There is growing evidence suggesting that statin therapy is associated with an increased risk
of new-onset diabetes [20]. In our study population of apparently healthy statin initiators, dia-
betes was present already at the time of statin initiation in 2% (247). When considering the dis-
tribution of all initiations of diabetes drugs (S1 Table), we did not find any signal of an
increasing frequency of new-onset diabetes over time. Dietary therapy was not recorded, and
we may have missed milder forms of diabetes.
Table 2. Estimation results of growth mixture models in the 4097 apparently healthy statin initiators with other drug purchases.
Model Log-
likelihood
Number of
parameters
BIC Entropy Lo-Mendell-Rubin
Likelihood Ratio Test
Proportion of individuals in class
2log
likelihood
P-
value
Linear GMM Class
1
Class
2
Class
3
Class
4
Class
5
1-class -26 136.3 3 52
298
NA NA NA 1.000 - - - -
2-class -25 916.7 6 51
883
0.718 422.27 <0.001 0.200 0.800 - - -
3-class -25 766.4 9 51
608
0.723 289.03 <0.001 0.112 0.196 0.691 - -
4-class -25 720.7 12 51
541
0.715 87.91 <0.001 0.600 0.196 0.171 0.033 -
5-class -25 720.7 15 51
566
0.755 89.28 <0.001 0.600 0.172 0.032 0.196 0.000
Quadratic
GMM
1-class -25 995.1 4 52
023
NA NA NA 1.000 - - - -
2-class -25 664.1 8 51
395
0.754 642.70 <0.001 0.220 0.780 - - -
3-class -25 511.7 12 51
123
0.749 296.05 <0.001 0.674 0.111 0.215 - -
4-class -25 467.2 16 51
068
0.737 82.30 <0.001 0.160 0.215 0.593 0.031 -
5-class -25 462.5 20 51
091
0.762 9.17 0.001 0.001 0.034 0.165 0.584 0.215
Abbreviations: BIC, Bayesian information criteria;
GMM, growth mixture models;
NA, not available
doi:10.1371/journal.pone.0117182.t002
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Few findings from other settings are available for comparison with our results. In nearly all
studies describing statin users, characteristics of individual patients have been aggregated.
However, in defining the apparently healthy, we used the method based on indication hierar-
chy described by a Danish group [21]. In 2006 in Denmark, approximately a quarter of new
statin users aged40 years were apparently healthy [11], which is in line with the 32% in
our data.
Vivid debate on the benefits of statin therapy among individuals at low CV disease risk is
ongoing [6, 22–28]. Global implementation of the recent ACC/AHA guidelines [5] would con-
siderably increase the number of potential candidates for statin therapy [25]. Our findings indi-
cate that two thirds of the apparently healthy statin initiators did not have such a change in
their health status that would have prompted initiation of other CV or diabetes medication
within 2 years of initiation. This suggests that a substantial proportion of initiators were at low
CV disease risk. Unfortunately, we did not have access to many important risk factors, such as
smoking, family history, blood pressure, and lipids, which hampers the assessment of the risk
level of our study population and the magnitude of potential statin overuse. However, in a pop-
ulation-based, cross-sectional study of a representative sample of Finnish adult population in
2007 it was estimated that one third of female statin users without established CV disease had a
10-year-risk of future events lower than 5% [29].
Our study has several strengths. Due to the large number of observations we had power to
detect differences in model fit across the models. This is crucial because the true number of
subpopulations remains unknown. We decided to model accumulation of additional CV or
Fig 2. Estimated class trajectories of 4-class quadratic growthmixturemodels (n = 4 097).Number of other cardiovascular or diabetes drug initiations
accumulated during the 24-month follow-up.
doi:10.1371/journal.pone.0117182.g002
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diabetes drugs among initiators of these drugs only as the model for the whole population of
statin initiators (GMM with zero-inflated Poisson) was not estimable. Adding covariates to
predict the class membership in the chosen model did not essentially change the classification
and thus, we did not report the results of those models; instead, we compared the baseline char-
acteristics of the classes via simple statistical tests. Loss to follow-up due to long-term institu-
tionalization or death was negligible in our cohort (1% of the initiators of additional CV or
diabetes drugs) and thus we did not need to extend the modeling to allow for missing not at
random pattern for missing data. During the time of data collection, all reimbursable drugs
were captured by the Prescription Register [30] and the definition of accumulating drugs was
kept constant as no novel CV drugs were launched onto the Finnish market in that period. Fur-
thermore, a CV drug purchase in the Prescription Register has been found to be a valid marker
of CV disease; when compared with the hospital discharge register, the sensitivity of the pre-
scription register in identifying patients with any CV disease was 99% in 2006 [12].
Table 3. Class-speciﬁc characteristics of the 4 097 statin initiators with other drug purchases during the 24-month follow-up.
Low and slow
accumulation
Low
accumulation
Moderate
accumulation
High
accumulation
P-
value
Posterior probability of patients by class, %a 20.1 59.2 17.1 3.6
Actual number (%) of patients 882 (21.5) 2431 (59.3) 655 (16.0) 129 (3.1)
Female, n (%) 486 (55.1) 1 216 (50.0) 253 (38.6) 30 (23.3) <0.001
Age group, n (%) 0.030
45–49 89 (10.1) 270 (11.1) 72 (11.0) 14 (10.9)
50–59 377 (42.7) 1 044 (42.9) 265 (40.5) 44 (34.1)
60–69 323 (36.6) 832 (34.2) 214 (32.7) 48 (37.2)
70–75 93 (10.5) 285 (11.7) 104 (15.9) 23 (17.8)
Age, mean (SD) 59.2 (7.4) 59.1 (7.70) 59.9 (7.9) 60.6 (8.05) 0.021
Hospitalized in the preceding 365 days, n
(%)
114 (12.9) 381 (15.7) 159 (24.3) 36 (27.9) <0.001
Adherenceb during the ﬁrst 365 days, mean
(SD)
0.66 (0.3) 0.69 (0.3) 0.71 (0.3) 0.78 (0.3) <0.001
No statin purchase since the ﬁrst 365 days,
n (%)
170 (19.3) 529 (21.8) 122 (18.6) 18 (14.0) 0.046
At least one purchase during the follow-up, n (%)
Diabetes drugs 160 (18.1) 390 (16.0) 152 (23.2) 30 (23.3) <0.001
Other antithrombotic agents but warfarin 118 (13.4) 285 (11.7) 143 (21.8) 50 (38.8) <0.001
Warfarin 28 (3.2) 64 (2.6) 51 (7.8) 23 (17.8) <0.001
Cardiac glycosides and antiarrhythmics 9 (1.0) 20 (0.8) 10 (1.5) 13 (10.1) <0.001
Organic nitrates 108 (12.2) 254 (10.4) 271 (41.4) 77 (59.7) <0.001
Centrally acting antihypertensive drugs 3 (0.3) 2 (0.1) 9 (1.4) 7 (5.4) <0.001
Diuretics 74 (8.4) 215 (8.8) 140 (21.4) 63 (48.8) <0.001
Beta blockers 235 (26.6) 613 (25.2) 402 (61.4) 118 (91.5) <0.001
Calcium channel blockers 79 (9.0) 250 (10.3) 145 (22.1) 59 (45.7) <0.001
ACEI or ARB 327 (37.1) 1229 (50.6) 431 (65.8) 118 (91.5) <0.001
Abbreviations: CV disease, cardiovascular disease;
ACEI, angiotensin-converting enzyme inhibitor;
ARB, angiotensin receptor blocker
aPosterior probability presented in Fig. 2.
bAdherence was deﬁned as proportion of days covered.
doi:10.1371/journal.pone.0117182.t003
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Our study had some limitations due to reliance on register data. We could not capture the
use of low-dose acetylsalicylic acid which is not reimbursed resulting in underestimation of the
number of accumulated drugs. Conversely, the number of initiations of antihypertensive drugs
may be higher than the number of initiators as a patient may need to test several antihyperten-
sive drugs in order to find the most suitable one. This may have inflated the number of accu-
mulated CV risks reflected by the number of drugs. As mentioned above, we did not have data
on all CV disease risk factors that may be detectable in patient records outside the hospital set-
ting to estimate the magnitude of CV risk in the study population. Furthermore, in theory, dis-
continuation of statin therapy due to adverse events could have resulted in a rapid initiation of
CV drugs for the modification of other CV risk factors. Unfortunately, we had no data on ad-
verse events during statin therapy, such as muscle symptoms or increase in hepatic enzyme lev-
els [5].
In conclusion, two thirds of the apparently healthy statin initiators did not use any other
CV or diabetes drug during the 2-year follow-up since statin initiation, suggesting that their
initial classification as being at low CV risk at the time of initiation was correct. However, one
third of the apparently healthy had concurrent drug-modifiable CV risk factors or even existing
CV disease at the time of statin initiation or shortly thereafter. In future register-based studies
of statin initiators at low CV risk, the definition of low-risk population should exclude statin
initiators who initiate other CV or diabetes medication simultaneously with statin in order to
avoid misclassification.
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